[Hepatitis virus infection among hemodialysis patients].

Aim, Patients And Methods: The high prevalence of anti-hepatitis C virus antibodies (anti-HCV) in hemodialyzed (HD) patients has been recognized since the early 1990s. Over the last decade, a significant decrease of anti-HCV prevalence among HD patients has been observed in many west European countries. In order to evaluate whether this trend is also present in Dialysis Center of Dubrava University Hospital, Zagreb, we tested HD patients for anti-HCV and HCV RNA in serum.

[Acute hepatitis C--an unresolved issue].

Introduction: The problem encountered on collecting a large number of cases of acute hepatitis C (AH-C) cases are the reduction in the incidence of new infections, clinically mild or completely asymptomatic disease, and absence of specific diagnostic tests to identify acute HCV infection and to distinguish it from acute exacerbation of chronic hepatitis C (CH-C).

Aim, Patients And Methods: The aim of this paper is to give an overview of 108 patients with AH-C hospitalized at Viral Hepatitis Unit, University Hospital of Infectious Diseases, during a 13-years period. Anti-HCV testing was started in 1990 and detection of HCV-RNA by PCR method in 1995.

Vaccination against hepatitis B: results of the analysis of 2000 population members in Croatia.

The results of the analysis of vaccination against hepatitis B performed in 2,000 persons of high-risk groups in Croatia are described. All susceptible non-immunocompromised persons (HBsAg, anti-HBs, and anti-HBc negative) received either plasma-derived vaccine (HB-Vax MSD, 20 micrograms per dose) or recombinant HB vaccine (ENGERIX-B, SKB, 20 micrograms per dose) according to a 0.1 and 6-month schedule.

Prevention of hepatitis B virus (HBV) infection in health-care workers after accidental exposure: a comparison of two prophylactic schedules.

The efficacy of hepatitis B (HB) vaccine alone or combined with hepatitis B immunoglobulin (HBIg) in preventing hepatitis B virus (HBV) infection was studied in a controlled trial. Recombinant HB vaccine (Engerix-B, 20 micrograms) was given to 40 susceptible health-care workers within three days of exposure (Group B). In another group of 37 medical professionals a single dose of HBIg (0.